Core Viewpoint - The article discusses the 16th Investor Relations Management Forum held in Yangzhou, where the winners of the Tianma Award for outstanding investor relations management were announced, highlighting the importance of effective communication between listed companies and their investors [1][2]. Group 1: Tianma Award Overview - The Tianma Award, organized by the Securities Times, is one of the earliest evaluation activities focused on investor relations management in China's capital market [2]. - The award aims to enhance the investor relations management level of listed companies and recognize those that excel in this field [2]. Group 2: Award Categories - Six categories of awards were presented: 1. Investor Relations Management Tianma Award 2. Outstanding Secretary of the Board Award 3. Excellent Team Award 4. Shareholder Return Award 5. Innovative Practice Award 6. Hong Kong Stock Market Investor Relations Management Tianma Award [2]. Group 3: Award Winners - A list of companies that received awards includes notable names such as BYD (002594), Mindray Medical (300760), and Yunnan Copper (000878) among others [3][4][5][6][8][9]. - The awards recognize companies across various sectors, indicating a broad commitment to improving investor relations [3][4][5][6][8][9]. Group 4: Notable Individuals - The article also highlights the names of secretaries of the board from awarded companies, showcasing the individuals who play a crucial role in investor relations [8][10]. - This recognition emphasizes the importance of leadership in fostering effective communication with investors [8][10]. Group 5: Hong Kong Stock Market Awards - The article lists the winners of the Hong Kong Stock Market Investor Relations Management Tianma Award, including companies like China Merchants Industry Holdings (1919.HK) and Kuaishou Technology (1024.HK) [19]. - This segment illustrates the growing recognition of investor relations practices in the Hong Kong market [19].

6月12日，"提质增效强信心 稳中求进促发展"——湖北辖区上市公司2025年投资者集体接待日活动暨 2024年度业绩说明会活动在全景路演举办。 图/湖北证监局一级巡视员刘昌华致辞 湖北省上市公司协会秘书长黄玲致辞表示：今天的网上集体接待日活动正是各方增进理解、凝聚共识的 重要契机，希望以此次线上相聚为新的起点，携手并肩、深化互信、凝聚智慧、共谋发展。 图/本次活动开场直播 本次活动是在湖北证监局指导下，湖北省上市公司协会联合深圳市全景网络有限公司举办，活动旨在加 强上市公司投资者沟通交流，引导上市公司做好市值管理工作，推动上市公司持续增强投资者回报，进 一步提升辖区上市公司整体投资价值。 湖北证监局一级巡视员刘昌华致辞指出：希望辖区上市公司要以此次集体接待日活动为契机，与投资者 充分交流，回应关切和诉求，切实履行社会责任。与此同时，希望辖区上市公司要进一步立足自身优 势，聚焦主业、深耕细作，打造核心竞争力，不断通过科技创新提升盈利和可持续发展能力，切实履行 社会责任。 在专业分享环节，TCL环保科技股份有限公司董秘、中国上市公司协会专家顾问讲师田瑞龙就《上市公 司市值管理绩效管理思路》做主题分享。 图/湖北省 ...

Core Viewpoint - The company is implementing a "Three New and Two Transformation" strategy, focusing on new products, new retail, new medical services, digitalization, and real estate securitization to enhance competitiveness and shareholder value [1][5]. New Product Strategy - The company has established a comprehensive new product strategy framework centered around CSO, covering business development, R&D registration, product evaluation, and marketing [1]. - In 2024, the total sales of the CSO brand promotion business reached 19.267 billion yuan, with 2,247 drug and device specifications introduced, including 52 products with sales exceeding 100 million yuan [1]. - The company's pharmaceutical manufacturing and OEM business achieved sales revenue of 3.007 billion yuan, a year-on-year increase of 21.49% [1]. New Retail Strategy - The company is building an integrated online and offline new retail service system, focusing on "ten thousand store franchises" [2]. - The number of franchise pharmacies has exceeded 29,000, generating sales revenue of 5.392 billion yuan, with C-end new retail sales revenue of 2.966 billion yuan [2]. - The logistics network covers over 96% of the country, serving more than 1,900 upstream brand enterprises [2]. New Medical Strategy - The company has developed an efficient clinic operation system and is advancing the "Nine Medical Clinics" membership alliance [2]. - Collaborating with Tencent Cloud, the company has created an AI-assisted diagnostic platform for clinics, enhancing diagnostic efficiency and patient experience [2]. - As of March, the number of member clinics reached 1,377, increasing the company's coverage in clinic channels [2]. Digitalization Strategy - The company has achieved digitalization across various operations, including supply chain management and decision support, and is advancing towards AI integration [3]. - In 2024, R&D investment in digitalization reached 346 million yuan, a year-on-year increase of 24.32% [3]. - The company’s digital platforms have improved operational efficiency and reduced costs, with significant recognition for its digital transformation initiatives [3]. Real Estate Securitization Strategy - The company has established a multi-tiered real estate equity operation platform, including public REITs and Pre-REITs, to attract scarce equity funds [4]. - The public REITs are based on high-quality pharmaceutical warehousing and logistics assets, with a total area of approximately 172,000 square meters recognized as a national intelligent logistics demonstration base [4]. - The company owns over 3 million square meters of pharmaceutical warehousing and logistics assets, with plans for further expansion of REITs listings [4]. Strategic Goals - The strategic objectives of the "Three New and Two Transformation" initiative include enhancing product competitiveness, improving profitability, reaching C-end customers, elevating overall management levels through digitalization, and achieving light asset operations to increase shareholder returns [5].

Summary of Key Points from Conference Call Records Company Overview - **Company**: 九州通 (Jiuzhoutong) - **Industry**: Pharmaceutical and Healthcare Services Core Insights and Arguments 1. **Dividend Distribution**: 九州通 announced a cash dividend of 0.20 yuan per share for the year 2024, with a record date of June 16, 2025, and a payment date of June 17, 2025. The total distribution is based on the total share capital minus shares held in the repurchase account, resulting in a distribution of 2.00 yuan for every 10 shares held [1][2][3]. 2. **Investment in Innovation**: The company established a strategic fund, "Wuhan Jiuying Venture Capital Fund," with a scale of 500 million yuan, focusing on investments in innovative drugs and high-end generics. The fund aims to accelerate the introduction of valuable new products through various collaboration models [3][4]. 3. **Product Development**: 九州通's subsidiary, 湖北九康通生物医药有限公司, is developing an oral antiviral drug for COVID-19, SHEN211, which has been accepted for clinical trial registration. This drug is noted as the first non-peptide 3CL protease inhibitor in China [3]. 4. **Logistics Technology**: The company has developed a comprehensive range of robotic products for logistics operations, including various types of handling robots suitable for different storage conditions. These products are already in use at logistics centers for major clients [4]. 5. **AI and Cloud Collaboration**: 九州通 is collaborating with leading tech companies like Alibaba Cloud and Tencent Cloud to develop AI applications in healthcare, including smart logistics and diagnostic systems. The company is also working on AI-driven solutions for various business scenarios [5]. Additional Important Information 1. **Environmental Initiatives**: The company is advancing its logistics park's photovoltaic project, achieving a total installed capacity of 20.57 MW, generating over 13 million kWh of electricity, and reducing CO2 emissions by approximately 11,021 tons [5]. 2. **Market Position**: 九州通 is recognized as the largest private pharmaceutical commercial enterprise in China and the first to be rated as a 5A logistics enterprise, highlighting its leadership in the industry [2]. 3. **Future Prospects**: The company is actively pursuing opportunities in the fields of innovative drugs, AI applications, and logistics technology, positioning itself for growth in the evolving healthcare landscape [3][5]. Company Overview - **Company**: 冰轮环境 (Binglun Environment) - **Industry**: Environmental Control and Energy Solutions Core Insights and Arguments 1. **Project Wins**: 冰轮环境 announced winning two large cold chain projects with a total bid amount exceeding 190 million yuan, representing about 2.9% of the company's audited revenue for 2024 [6][7]. 2. **Product Offerings**: The company specializes in artificial environment control technologies and energy utilization, with key products including various types of compressors and industrial heat pumps [7]. 3. **Research and Development**: The company is engaged in developing solid oxide batteries and has been involved in projects related to controlled nuclear fusion, emphasizing its role in advanced technology sectors [7]. Additional Important Information 1. **Green Technology**: 冰轮环境's products have been recognized in the national green data center technology product directory, showcasing their application in major data centers across China [8]. 2. **Industry Applications**: The company's cooling solutions have been utilized in significant venues for the Beijing Winter Olympics, demonstrating their capability in high-profile projects [8]. 3. **Strategic Collaborations**: The company is exploring partnerships in the robotics field, particularly in logistics applications, indicating a focus on integrating advanced technologies into their service offerings [9]. Conclusion The conference call records highlight significant developments in both 九州通 and 冰轮环境, showcasing their strategic initiatives in innovation, technology, and market leadership within their respective industries.

换股进展的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 依据募集说明书的相关约定，九州通医药集团股份有限公司（以下简称"公 司"）控股股东楚昌投资集团有限公司（以下简称"楚昌投资"）2022年非公开发 行的可交换公司债券（以下简称"可交债"）持有人于2024年12月19日至2025 年6月9日期间行使换股权利，导致楚昌投资的持股比例被动下降，不触及要约收 购。 证券代码：600998 证券简称：九州通 公告编号：临 2025-044 九州通医药集团股份有限公司 关于控股股东 2022 年非公开发行可交换公司债券 注：本次变动所涉及股份均享有表决权，不存在表决权委托或受限等任何权利限制 或被限制转让的情况。 本次权益变动为可交债持有人依据募集说明书的相关约定行使换股权利所 致，不存在违反《证券法》《上市公司收购管理办法》《上市公司股东减持股份 管理暂行办法》等法律法规和上海证券交易所业务规则等相关规定及相关承诺。 本次可交债换股后，楚昌投资仍为公司控股股东。 二、本次可交债持有人换股前后，控股股 ...

邮政编码：100022 电话：010-65219696 传真：010-88381869 北京海润天睿律师事务所 关于九州通医药集团股份有限公司差异化分红事项的 法律意见书 中国·北京 朝阳区建外大街甲14号广播大厦5层、9层、10层、13层、17层 二〇二五年五月 北京海润天睿律师事务所 关于九州通医药集团股份有限公司差异化分红事项的 法律意见书 致：九州通医药集团股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受九州通医药集团股份有 限公司（以下简称"公司"）委托，根据《中华人民共和国公司法》（以下简称 《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、中国证券 监督管理委员会（以下简称"中国证监会"）发布的《上市公司股份回购规则》 （以下简称《回购规则》）、上海证券交易所发布的《上海证券交易所上市公司 自律监管指引第 7 号——回购股份》（以下简称"《自律指引 7 号》"）等法律、 法规和规范性文件的规定，以及《九州通医药集团股份有限公司章程》（以下简 称《公司章程》）的规定，就公司 2024 年度利润分配涉及的差异化分红特殊除 权除息处理（以下简称"本次差异化分红"）相关事项出具本 ...

一、申请差异化权益分派事由 2025 年 5 月 23 日，公司召开 2024 年年度股东会，审议通过了《关于公司 2024 年度利润分配预案的议案》，公司拟以权益分派股权登记日登记的总股本 扣除回购专户股份为基数，向全体普通股股东每 10 股派发现金红利 2.00 元（含 税），剩余未分配利润结转以后年度；公司 2024 年度不进行资本公积金转增股 本，不送红股。 根据相关规定，公司申请差异化权益分派特殊除权除息业务，具体原因如下： 2024 年 6 月 17 日，公司召开第六届董事会第五次会议，审议通过了《关于 以集中竞价交易方式回购公司股票的议案》。截至 2024 年 12 月 16 日，回购期 限届满，公司累计回购股票 5,603.65 万股。截至九州通本次差异化权益分派特殊 除权除息事项申请日，公司回购专用账户的股票数量为 5,603.65 万股。 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等有关规 定，公司回购专户的股份不参与利润分配，因此公司申请 2024 年度利润分配实 施差异化权益分派，公司权益分派股份基数与公司股本总数相差 56,036,500 股。 二、本次差异化权益 ...

Group 1 - The Shanghai Central Rise Leading Enterprises Index (H50014) experienced a decline of 0.46%, closing at 3020.69 points with a trading volume of 15.059 billion yuan [1] - Over the past month, the index has decreased by 1.21%, by 2.68% over the last three months, and by 0.83% year-to-date [1] - The index is composed of leading companies from various secondary industries within selected regions, providing a reference for investors interested in China's regional economic development [1] Group 2 - The top ten weighted companies in the index include: Daqin Railway (16.7%), Luoyang Molybdenum (14.89%), Shanxi Fenjiu (14.01%), Conch Cement (13.33%), Jiangxi Copper (11.22%), JinkoSolar (3.81%), Changsha Bank (3.35%), Jiuzhoutong (2.0%), Luan Environmental Energy (1.99%), and Wentai Technology (1.93%) [1] - The index is fully represented by companies listed on the Shanghai Stock Exchange [1] Group 3 - The industry composition of the index shows that materials account for 41.97%, industrials for 25.80%, consumer staples for 14.39%, financials for 5.05%, healthcare for 4.36%, energy for 3.77%, information technology for 2.74%, communication services for 1.01%, utilities for 0.47%, and consumer discretionary for 0.46% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.20元（含税） 相关日期 证券代码：600998 证券简称：九州通 公告编号：临 2025-043 九州通医药集团股份有限公司 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/16 | － | 2025/6/17 | 2025/6/17 | 差异化分红送转： 是 一、 通过分配方案的股东会届次和日期 本次利润分配方案经九州通医药集团股份有限公司（以下简称"公司"）2025 年 5 月 23 日 的2024年年度股东会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 3. 差异化分红送转方案： （1）本次差异化分红方案 根据公司 2024 年年度股东会审议通过的《关于公司 2024 年度利润分配预案的议案》，公 司拟以权益分派股权登记日登记的 ...

证券代码：600998 证券简称：九州通 公告编号：临 2025-044 九州通医药集团股份有限公司 关于控股股东 2022 年非公开发行可交换公司债券 换股进展的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 依据募集说明书的相关约定，九州通医药集团股份有限公司（以下简称"公 司"）控股股东楚昌投资集团有限公司（以下简称"楚昌投资"）2022年非公开发 行的可交换公司债券（以下简称"可交债"）持有人于2024年12月19日至2025 年6月9日期间行使换股权利，导致楚昌投资的持股比例被动下降，不触及要约收 购。 ● 本次可交债换股不会导致公司控股股东及实际控制人发生变化。 ● 本次可交债换股后，楚昌投资及其一致行动人持有公司股权比例从 关约定，"楚昌投资集团有限公司2022年面向专业投资者非公开发行可交换公司 债券（第一期）"（以下简称"22楚EB01"）的持有人于2024年12月19日至2025 年6月9日期间行使换股权利，累计换股14,477,602股，导致公司控股股东楚昌投 资及其一致行 ...